Table 2.
Baseline characteristics of patients with blood samples collected and analyzed for this companion study compared with all other patients registered in the treatment trial CALGB(Alliance)/SWOG 80405a
| Baseline characteristics | Blood sample analyzed (n = 1086) | No blood sample analyzed (n = 1240) | Entire trial cohort (N = 2326) |
|---|---|---|---|
| No. deaths | 932 | 1041 | 1973 |
| Female, No. (%) | 447 (41.2) | 524 (42.3) | 971 (41.7) |
| Age, median y (Q1-Q3), y | 60 (51-68) | 59 (51-67) | 59 (51-68) |
| Race, No. (%) | |||
| White | 931 (85.7) | 965 (77.8) | 1896 (81.5) |
| Black | 113 (10.4) | 165 (13.3) | 278 (12.0) |
| Other | 42 (3.9) | 110 (8.9) | 152 (6.5) |
| Performance status, No. (%) | |||
| ECOG 0 | 657 (60.5) | 704 (56.8) | 1361 (58.5) |
| ECOG 1 or 2 | 429 (39.5) | 536 (43.2) | 965 (41.5) |
| Planned chemotherapy, No. (%) | |||
| FOLFIRI | 250 (23.0) | 280 (22.6) | 530 (22.8) |
| mFOLFOX6 | 836 (77.0) | 960 (77.4) | 1796 (77.2) |
| Prior adjuvant chemotherapy, No. (%) | 151 (13.9) | 183 (14.8) | 334 (14.4) |
| Prior radiation therapy, No. (%) | 102 (9.4) | 103 (8.3) | 205 (8.8) |
| Assigned treatment arm, No. (%) | |||
| Bevacizumab | 434 (40.0) | 463 (37.3) | 897 (38.6) |
| Cetuximab | 443 (40.8) | 454 (36.6) | 897 (38.6) |
| Bevacizumab + cetuximab | 209 (19.2) | 323 (26.0) | 532 (22.9) |
| KRAS, No. (%) | |||
| Wild-type | 720 (66.3) | 550 (44.4) | 1270 (54.6) |
| Mutant | 319 (29.4) | 139 (11.2) | 458 (19.7) |
| Indeterminate | 47 (4.3) | 551 (44.4) | 598 (25.7) |
| Tumor sidedness, No. (%) | |||
| Right or transverse colon | 380 (35.0) | 405 (32.7) | 785 (33.7) |
| Left colon or rectum | 643 (59.2) | 693 (55.9) | 1336 (57.4) |
| Unknown | 63 (5.8) | 142 (11.5) | 205 (8.8) |
| BMI, median (Q1-Q3), kg/m2 | 27 (24-32) | 27 (24-31) | 27 (24-31) |
| Metastases involving multiple regions, No. (%) | 584 (54.0) | 677 (55.8) | 1261 (55.0) |
| WBC >10x109/L, No. (%) | 198 (18.3) | 252 (20.6) | 450 (19.5) |
| Hgb <11g/L, No. (%) | 879 (81.1) | 986 (80.6) | 1865 (80.8) |
a
BMI = body mass index; CALGB(Alliance) = Cancer and Leukemia Group B, now Alliance for Clinical Trials in Oncology; ECOG = Eastern Cooperative Oncology Group; FOLFIRI = leucovorin, 5-fluorouracil, and irinotecan; Hgb = hemoglobin; mFOLFOX6 = leucovorin, 5-fluorouracil, and oxaliplatin; Q = quintile; WBC = white blood cell count.